AlRuthia, Y.; Almutairi, K.K.; Aljammaz, N.A.; Alsuwayegh, A.; Alanazi, M.A.; AlSulaiman, R.F.; Alfaori, T.M.; Alabdan, N.
Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study. Healthcare 2025, 13, 2428.
https://doi.org/10.3390/healthcare13192428
AMA Style
AlRuthia Y, Almutairi KK, Aljammaz NA, Alsuwayegh A, Alanazi MA, AlSulaiman RF, Alfaori TM, Alabdan N.
Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study. Healthcare. 2025; 13(19):2428.
https://doi.org/10.3390/healthcare13192428
Chicago/Turabian Style
AlRuthia, Yazed, Khlood Khaled Almutairi, Norah Abdulaziz Aljammaz, Aseel Alsuwayegh, Miteb A. Alanazi, Rasha Fahad AlSulaiman, Tareq Majed Alfaori, and Numan Alabdan.
2025. "Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study" Healthcare 13, no. 19: 2428.
https://doi.org/10.3390/healthcare13192428
APA Style
AlRuthia, Y., Almutairi, K. K., Aljammaz, N. A., Alsuwayegh, A., Alanazi, M. A., AlSulaiman, R. F., Alfaori, T. M., & Alabdan, N.
(2025). Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study. Healthcare, 13(19), 2428.
https://doi.org/10.3390/healthcare13192428
